Article

BRAF inhibitor resistance confers increased sensitivity to mitotic inhibitors

2021-04-15

Abstract excerpt

Single agent and combination therapy with BRAF V600E/K and MEK inhibitors have remarkable efficacy against melanoma tumors with activating BRAF mutations, but in most cases resistance eventually develops. The purpose of this study is to uncover pharmacological vulnerabilities of BRAFi-resistant melanoma cells, with the goal of identifying new therapeutic options for patients whose tumors have developed resistance...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 696d5e7e-976a-5611-9265-7dc34d7e03f3
DOI: 10.1101/2021.04.15.439990

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BRAF inhibitor resistance confers increased sensitivity to mitotic inhibitorsDOI 10.1101/2021.04.15.439990Read

Multiple cancer types rapidly escape from multiple MAPK inhibitors to generate mutagenesis-prone subpopulationsSemantic proximity Read

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.Semantic proximity Read

Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanomaSemantic proximity Read

Mitotic Poisons In Cancer PharmacotherapySemantic proximity Read

Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLC.Semantic proximity Read

Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development.Semantic proximity Read

Mitosis-targeted anti-cancer therapies: where they standSemantic proximity Read

Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirinSemantic proximity Read

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant MelanomaSemantic proximity Read

Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.Semantic proximity Read

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceSemantic proximity Read